 UNIONDALE, N.Y., Sept. 02, 2021 GLOBE NEWSWIRE -- Angion Biomedica Corp NASDAQ:ANGN, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences MedTech Summit. 